Alnylam Pharmaceuticals Financials
| ALNY Stock | USD 290.70 0.00 0.00% |
| Current Value | Last Year | Change From Last Year | 10 Year Trend | ||||||
|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 2.64 | 2.7778 |
|
|
Investors should never underestimate Alnylam Pharmaceuticals' ability to pay suppliers on time, ensure interest payments are not accumulating, and correctly time where and how to reinvest extra cash. Individual investors need to monitor Alnylam Pharmaceuticals' cash flow, debt, and profitability to make informed and accurate decisions about investing in Alnylam Pharmaceuticals.
Net Income |
|
Alnylam | Select Account or Indicator |
Understanding current and past Alnylam Pharmaceuticals Financials, including the trends in assets, liabilities, equity and income are directly related to making proper and timely investing decisions. All of Alnylam Pharmaceuticals' financial statements are interrelated, with each one affecting the others. For example, an increase in Alnylam Pharmaceuticals' assets may result in an increase in income on the income statement.
Alnylam Pharmaceuticals Earnings Geography
Please note, the imprecision that can be found in Alnylam Pharmaceuticals' accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of Alnylam Pharmaceuticals. Check Alnylam Pharmaceuticals' Beneish M Score to see the likelihood of Alnylam Pharmaceuticals' management manipulating its earnings.
Alnylam Pharmaceuticals Stock Summary
Alnylam Pharmaceuticals competes with ProQR Therapeutics, Wave Life, Blueprint Medicines, Apellis Pharmaceuticals, and Incyte. Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. The company was founded in 2002 and is headquartered in Cambridge, Massachusetts. Alnylam Pharmaceuticals operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 1665 people.Specialization | Health Care, Pharmaceuticals, Biotechnology & Life Sciences |
| Instrument | USA Stock View All |
| Exchange | NASDAQ Exchange |
| ISIN | US02043Q1076 |
| CUSIP | 02043Q107 |
| Location | Massachusetts; U.S.A |
| Business Address | 675 West Kendall |
| Sector | Biotechnology |
| Industry | Health Care |
| Benchmark | Dow Jones Industrial |
| Website | www.alnylam.com |
| Phone | 617 551 8200 |
| Currency | USD - US Dollar |
Alnylam Pharmaceuticals Key Financial Ratios
| Return On Equity | -15.01 | ||||
| Profit Margin | (0.12) % | ||||
| Operating Margin | (0.18) % | ||||
| Price To Sales | 16.32 X | ||||
| Revenue | 2.25 B |
Alnylam Pharmaceuticals Key Balance Sheet Accounts
| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 (projected) | ||
| Total Assets | 3.4B | 3.6B | 3.5B | 3.8B | 4.2B | 4.5B | |
| Other Current Liab | 355.9M | 395.2M | 545.5M | 713.0M | 1.0B | 1.1B | |
| Net Debt | 24.6M | 177.6M | 453.9M | 1.9B | (127.1M) | (133.5M) | |
| Retained Earnings | (4.6B) | (5.4B) | (6.6B) | (7.0B) | (7.3B) | (6.9B) | |
| Accounts Payable | 52.0M | 73.4M | 98.1M | 55.5M | 88.4M | 92.8M | |
| Cash | 496.6M | 820.0M | 866.4M | 812.7M | 127.1M | 120.8M | |
| Other Assets | 32.9M | 40.7M | 101.1M | 115.5M | 132.8M | 139.4M | |
| Other Current Assets | 625.5M | 88.1M | 132.9M | 126.4M | 117.0M | 96.0M | |
| Total Liab | 2.4B | 3.1B | 3.7B | 4.1B | 4.2B | 4.4B | |
| Total Current Assets | 2.2B | 2.9B | 2.7B | 3.0B | 3.3B | 3.5B | |
| Other Liab | 327.7M | 352.3M | 1.4B | 406.4M | 467.3M | 490.7M | |
| Short Term Debt | 50.2M | 77.6M | 82.3M | 96.5M | 41.9M | 42.6M | |
| Net Receivables | 102.4M | 198.6M | 238.0M | 327.8M | 405.3M | 425.6M | |
| Common Stock | 1.2M | 1.2M | 1.2M | 1.3M | 1.3M | 831.2K | |
| Net Tangible Assets | 1.4B | 1.0B | 588.2M | (158.2M) | (182.0M) | (172.9M) | |
| Capital Surpluse | 5.2B | 5.6B | 6.1B | 6.5B | 7.4B | 7.8B | |
| Inventory | 92.3M | 122.7M | 129.0M | 89.1M | 78.5M | 82.4M |
Alnylam Pharmaceuticals Key Income Statement Accounts
An income statement is very similar to a cash flow statement, but instead of showing net revenue minus expenses, it only includes earnings before interest and taxes (EBIT). This number does not have all of the same line items that are on a cash flow statement, but it leaves out non-cash expenses like depreciation and amortization. For example, if you bought $100 worth of goods from Walmart (WMT) using your debit card that has an interest rate of 20%, then paid off the balance at the end of the month with a credit card that charges 30% interest, you would have an income statement showing EBIT of $80 because your expenses are lower than the amount that went into your pocket.
| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 (projected) | ||
| Interest Expense | 84.5M | 143.0M | 156.0M | 121.2M | 141.9M | 149.0M | |
| Operating Income | (828.4M) | (708.7M) | (785.1M) | (282.2M) | (176.9M) | (185.7M) | |
| Ebit | (771.1M) | (709.1M) | (971.0M) | (312.3M) | (235.5M) | (247.3M) | |
| Research Development | 654.8M | 792.2M | 883.0M | 1.0B | 1.1B | 1.2B | |
| Ebitda | (736.3M) | (661.6M) | (926.6M) | (258.2M) | (178.8M) | (187.8M) | |
| Net Income | (858.3M) | (852.8M) | (1.1B) | (440.2M) | (278.2M) | (292.1M) | |
| Income Tax Expense | 2.7M | 680K | 4.2M | 6.7M | 99.2M | 104.2M | |
| Total Revenue | 492.9M | 844.3M | 1.0B | 1.8B | 2.2B | 2.4B | |
| Gross Profit | 414.8M | 704.1M | 868.6M | 1.5B | 1.9B | 2.0B | |
| Cost Of Revenue | 78.1M | 140.1M | 168.8M | 310.4M | 323.4M | 186.7M | |
| Income Before Tax | (855.6M) | (852.1M) | (1.1B) | (433.5M) | (178.9M) | (187.9M) | |
| Interest Income | 11.8M | 1.6M | 24.8M | 95.6M | 122.0M | 128.1M | |
| Tax Provision | 2.7M | 680K | 4.2M | 6.7M | (99.2M) | (94.3M) | |
| Net Interest Income | (72.7M) | (141.4M) | (131.2M) | (25.7M) | (19.9M) | (20.9M) |
Alnylam Pharmaceuticals Key Cash Accounts
Cash flow analysis captures how much money flows into and out of Alnylam Pharmaceuticals. It measures of how well Alnylam is doing because it can show the actual money that comes into and out of the Company from sales instead of measuring expenses against revenue to determine earnings. You have to read the cash flow statement in three sections. The first section shows how much money Alnylam Pharmaceuticals brought in, usually known as net revenue or sales. This is different from earnings because it does not include expenses when determining net revenue for use on this part of the cash flow statement. Next, are operating activities, which show how much money Alnylam had leftover after paying for its expenses. This number can be calculated in two ways: by subtracting the total of all operating expenses from net revenue or by adding up changes to cash and other assets or liabilities on this part of the statement. The third section is about investing activities, which shows what Alnylam Pharmaceuticals has done with the money that it received from the sale of assets or what it spent to acquire new ones. This section can be broken down into two parts: investing in existing businesses (in other words, buying more stock) and investing in non-business activities like paying off debt or making acquisitions.
| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 (projected) | ||
| Change In Cash | (50.6M) | 323.1M | 46.4M | (53.7M) | 153.8M | 161.5M | |
| Free Cash Flow | (685.3M) | (718.1M) | (613.3M) | 41.9M | (42.6M) | (44.7M) | |
| Depreciation | 74.4M | 89.7M | 85.6M | 97.0M | 56.7M | 59.5M | |
| Other Non Cash Items | 95.8M | 174.2M | 309.2M | 214.9M | 47.9M | 53.0M | |
| Capital Expenditures | 70.4M | 76.4M | 72.1M | 62.2M | 34.3M | 39.9M | |
| Net Income | (858.3M) | (852.8M) | (1.1B) | (440.2M) | (278.2M) | (292.1M) | |
| End Period Cash Flow | 499.0M | 822.2M | 868.6M | 814.9M | 968.7M | 1.0B | |
| Change To Netincome | 201.8M | 156.7M | 223.4M | 307.7M | 353.9M | 371.6M | |
| Change To Inventory | (35.4M) | (26.4M) | (34.1M) | 18.4M | 13.6M | 14.3M | |
| Investments | (334.0M) | (192.6M) | 169.4M | (235.6M) | (116.8M) | (122.7M) | |
| Change Receivables | (24.2M) | (56.2M) | (101.8M) | (45.6M) | (41.0M) | (39.0M) |
Alnylam Financial Ratios Relationships
Comparative valuation techniques use various fundamental indicators to help in determining Alnylam Pharmaceuticals's current stock value. Our valuation model uses many indicators to compare Alnylam Pharmaceuticals value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Alnylam Pharmaceuticals competition to find correlations between indicators driving Alnylam Pharmaceuticals's intrinsic value. More Info.Alnylam Pharmaceuticals is rated below average in return on equity category among its peers. It is rated below average in return on asset category among its peers . At this time, Alnylam Pharmaceuticals' Return On Equity is fairly stable compared to the past year. The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Alnylam Pharmaceuticals' earnings, one of the primary drivers of an investment's value.Alnylam Pharmaceuticals' Earnings Breakdown by Geography
Alnylam Pharmaceuticals Systematic Risk
Alnylam Pharmaceuticals' systematic risk plays a vital role in portfolio allocation when considering its stock to be added to a well-diversified portfolio. Alnylam Pharmaceuticals volatility which cannot be eliminated through diversification, requires returns over the risk-free rate. Over the long run, a well-diversified portfolio provides returns that match its exposure to systematic risk. In this case, investors face a trade-off between expected returns and systematic risk and, therefore, can only reduce a portfolio's exposure to systematic risk by sacrificing expected returns on the portfolio.
The function did not generate any output. Please change time horizon or modify your input parameters. The output start index for this execution was one with a total number of output elements of sixty. The Beta measures systematic risk based on how returns on Alnylam Pharmaceuticals correlated with the market. If Beta is less than 0 Alnylam Pharmaceuticals generally moves in the opposite direction as compared to the market. If Alnylam Pharmaceuticals Beta is about zero movement of price series is uncorrelated with the movement of the benchmark. if Beta is between zero and one Alnylam Pharmaceuticals is generally moves in the same direction as, but less than the movement of the market. For Beta = 1 movement of Alnylam Pharmaceuticals is generally in the same direction as the market. If Beta > 1 Alnylam Pharmaceuticals moves generally in the same direction as, but more than the movement of the benchmark.
Today, most investors in Alnylam Pharmaceuticals Stock are looking for potential investment opportunities by analyzing not only static indicators but also various Alnylam Pharmaceuticals' growth ratios. Consistent increases or decreases in fundamental ratios usually indicate a possible pattern that can be successfully translated into profits. However, when comparing two companies, knowing each company's growth growth rates may not be enough to decide which company is a better investment. That's why investors frequently use static breakdown of Alnylam Pharmaceuticals growth as a starting point in their analysis.
Price Earnings To Growth Ratio |
|
Alnylam Pharmaceuticals March 24, 2025 Opportunity Range
Along with financial statement analysis, the daily predictive indicators of Alnylam Pharmaceuticals help investors to analyze its daily demand and supply, volume, patterns, and price swings to determine the real value of Alnylam Pharmaceuticals. We use our internally-developed statistical techniques to arrive at the intrinsic value of Alnylam Pharmaceuticals based on widely used predictive technical indicators. In general, we focus on analyzing Alnylam Stock price patterns and their correlations with different microeconomic environment and drivers. We also apply predictive analytics to build Alnylam Pharmaceuticals's daily price indicators and compare them against related drivers.
| Downside Deviation | 2.08 | |||
| Information Ratio | 0.1095 | |||
| Maximum Drawdown | 15.4 | |||
| Value At Risk | (3.48) | |||
| Potential Upside | 4.69 |
Additional Tools for Alnylam Stock Analysis
When running Alnylam Pharmaceuticals' price analysis, check to measure Alnylam Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Alnylam Pharmaceuticals is operating at the current time. Most of Alnylam Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Alnylam Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Alnylam Pharmaceuticals' price. Additionally, you may evaluate how the addition of Alnylam Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.